Study analysis · Journal of the Endocrine Society · 2025
Steroids save your lungs—but could be eating your muscles alive.
A new drug in mice stopped steroids from making muscles shrink, even helping them grow a little.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study tested a new idea in mice — it gave them a special medicine and saw their muscles didn't shrink as much. But it didn't prove the medicine caused the change, because the mice weren't randomly assigned and there were too few of them. It's like noticing your friend's plant looks better after you sang to it — maybe it helped, but you can't be sure.
What’s the bottom line?
Steroids help lung inflammation but can make muscles weaker. This study tested a new drug in mice that blocks a signal causing muscle loss.
How strong is this study?
The study tried to be careful by using the same type of mice and measuring things the same way, but it didn't randomly pick which mice got the medicine — that's like choosing your favorite friends to test a new game on. That makes it harder to trust the results, because maybe those mice were just luckier to begin with.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
33 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control group+15/15
- Sample size (n=12)+1.2/20
- Follow-up+10/10
100 / 100
54 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 516 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. This is an animal study with no randomization, no blinding (unknown), and a very small sample size (n=12 total). Without randomization or control for confounders, it cannot establish cause-effect relationships, only observe associations within a specific experimental setup.
Major COI
Major conflicts that significantly reduce study credibility
The study was conducted using a proprietary antibody (CDD866) provided by Versanis Bio, a company with a direct interest in the outcome, and while authors disclosed no conflicts, the funder's provision of the experimental drug without clarification of involvement raises significant bias concerns.
Funders
Conflict Details
Versanis Bio: Provided the experimental compound CDD866 for use in the study
Although all authors declared 'None' for conflicts of interest, the provision of the investigational drug (CDD866) by Versanis Bio — a company with a commercial interest in the success of ActIIB-R blockade — constitutes a major conflict. No details are given about whether the funder influenced study design, analysis, or interpretation. The lack of a funding statement further limits transparency.
Key takeaways
- 01
Mice on steroids lost 6.6% of leg muscle; mice on steroids + the new drug kept their muscle (0.7% gain).
- 02
Body weight dropped 6.4% with steroids alone, but stayed stable with the drug.
- 03
A 7% difference in muscle volume could mean the difference between being able to walk or needing help — a meaningful change for patients.
Surprising findings
- Glucocorticoid treatment did not increase expression of Atrogin-1 or MuRF1, the two most famous muscle-wasting genes.For decades, scientists assumed these genes were the main drivers of steroid-induced muscle loss. This study shows they may not even be involved—meaning the entire research direction might need a reset.
- CDD866 prevented body weight loss despite no change in food intake or lung inflammation.Body weight dropped 6.4% with steroids alone—but stayed stable with CDD866, even though the drug didn’t reduce lung inflammation. This suggests it’s directly protecting muscle and fat tissue, not just calming the lungs.
Practical takeaways
If you or a loved one has COPD and is on steroids, ask your doctor about muscle-strengthening programs—this study suggests protecting muscle is critical during flare-ups.
This was tested in mice, not humans. CDD866 is not yet approved for human use.
low confidenceFitness coaches working with COPD patients should prioritize resistance training during steroid treatment—this study implies muscle loss is preventable, not inevitable.
No human data yet. Don’t assume this drug will be available soon.
medium confidenceWhy this study matters
Steroids vs. Muscle Loss
In mice with COPD-like lung damage, dexamethasone (a common steroid) caused a 6.6% loss in hindlimb muscle volume and a 6.4% drop in body weight. But when given CDD866—a drug that blocks the ActIIB-R receptor—muscle volume increased by 0.7% and body weight stayed stable.
Millions of COPD patients rely on steroids during flare-ups, but muscle wasting can leave them too weak to walk or breathe easily. This could mean a future drug that lets steroids work without the side effect.
The Mystery of the Silent Genes
Despite muscle loss, the study found no significant increase in Atrogin-1 or MuRF1—two genes usually blamed for muscle breakdown. In fact, CDD866 showed a trend toward reducing them (p=0.053 and p=0.076), suggesting steroids may wreck muscle through unknown pathways.
This flips the script: we thought we knew how steroids destroy muscle—but now we might be wrong. That means new drug targets could be hiding in plain sight.
The 7.3% Muscle Gap That Could Save Lives
The difference between the steroid-only group (-6.6%) and the drug-treated group (+0.7%) was a 7.3 percentage point gap in muscle volume change—enough to mean the difference between walking independently or needing help.
For elderly COPD patients, losing 7% muscle isn’t just about strength—it’s about staying out of the hospital, avoiding falls, and living at home.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Steroids help lung inflammation but can make muscles weaker. This study tested a new drug in mice that blocks a signal causing muscle loss.
Research results
Mice on steroids lost 6.6% of leg muscle; mice on steroids + the new drug kept their muscle (0.7% gain). Body weight dropped 6.4% with steroids alone, but stayed stable with the drug.
What this means - more context
A 7% difference in muscle volume could mean the difference between being able to walk or needing help — a meaningful change for patients.
This study tests whether blocking the activin type IIB receptor (ActIIB-R) with CDD866 can prevent muscle wasting in a mouse model of glucocorticoid-treated COPD exacerbation.
In a mouse model of COPD exacerbation induced by elastase and LPS, glucocorticoid treatment caused significant muscle and body weight loss. Co-treatment with CDD866, an ActIIB-R blocker, prevented muscle volume loss (increased by 0.7% vs. -6.6% in glucocorticoid-only group, p<0.05) and body weight loss, while showing a non-significant trend toward reduced expression of atrophy genes Atrogin-1 and MuRF1.
Methods Used
Male C57BL/6J mice (n=12/group) received elastase to induce emphysema, followed by LPS to trigger exacerbation. Dexamethasone (glucocorticoid) and/or CDD866 (20 mg/kg) were administered subcutaneously. Muscle volume was measured via micro-CT, muscle weight was post-mortem weighed, and atrogene expression was analyzed.
Main Finding
CDD866 significantly increased hindlimb muscle volume by 7.3 percentage points compared to glucocorticoid-only treatment (-6.6% vs. +0.7%, p<0.05) and prevented glucocorticoid-induced body weight loss (-6.4% vs. no change).
Confidence Level
Moderate — controlled experimental design with direct measurements and reported p-values, but small sample size (n=12/group), no randomization, and trends in molecular data not statistically significant.
Study Flags
Red Flags
- •Small sample size (n=12/group)
- •No randomization reported
- •Mouse model only — human relevance unknown
Surprising Findings
Glucocorticoid treatment did not increase expression of Atrogin-1 or MuRF1, the two most famous muscle-wasting genes.
For decades, scientists assumed these genes were the main drivers of steroid-induced muscle loss. This study shows they may not even be involved—meaning the entire research direction might need a reset.
Practical Takeaways
If you or a loved one has COPD and is on steroids, ask your doctor about muscle-strengthening programs—this study suggests protecting muscle is critical during flare-ups.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 516 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Animal Cohort Study
Subject
Lower probability
on the GRADE evidence scale
This study tested a new idea in mice — it gave them a special medicine and saw their muscles didn't shrink as much. But it didn't prove the medicine caused the change, because the mice weren't randomly assigned and there were too few of them. It's like noticing your friend's plant looks better after you sang to it — maybe it helped, but you can't be sure.
Major conflicts — industry funding with significant control over the research. Reporting score and overall score cap have been reduced.
Strengths
- Clear experimental groups with defined interventions
- Use of objective measures (micro-CT, muscle weight, gene expression)
- Control groups included for comparison
Weaknesses
- No randomization — groups may differ at baseline
- Blinding status unknown — risk of measurement bias
- Very small sample size (n=12 total)
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Steroids help lung inflammation but can make muscles weaker. This study tested a new drug in mice that blocks a signal causing muscle loss.
Research results
Mice on steroids lost 6.6% of leg muscle; mice on steroids + the new drug kept their muscle (0.7% gain). Body weight dropped 6.4% with steroids alone, but stayed stable with the drug.
What this means - more context
A 7% difference in muscle volume could mean the difference between being able to walk or needing help — a meaningful change for patients.
This study tests whether blocking the activin type IIB receptor (ActIIB-R) with CDD866 can prevent muscle wasting in a mouse model of glucocorticoid-treated COPD exacerbation.
In a mouse model of COPD exacerbation induced by elastase and LPS, glucocorticoid treatment caused significant muscle and body weight loss. Co-treatment with CDD866, an ActIIB-R blocker, prevented muscle volume loss (increased by 0.7% vs. -6.6% in glucocorticoid-only group, p<0.05) and body weight loss, while showing a non-significant trend toward reduced expression of atrophy genes Atrogin-1 and MuRF1.
Methods Used
Male C57BL/6J mice (n=12/group) received elastase to induce emphysema, followed by LPS to trigger exacerbation. Dexamethasone (glucocorticoid) and/or CDD866 (20 mg/kg) were administered subcutaneously. Muscle volume was measured via micro-CT, muscle weight was post-mortem weighed, and atrogene expression was analyzed.
Main Finding
CDD866 significantly increased hindlimb muscle volume by 7.3 percentage points compared to glucocorticoid-only treatment (-6.6% vs. +0.7%, p<0.05) and prevented glucocorticoid-induced body weight loss (-6.4% vs. no change).
Confidence Level
Moderate — controlled experimental design with direct measurements and reported p-values, but small sample size (n=12/group), no randomization, and trends in molecular data not statistically significant.
Study Flags
Red Flags
- •Small sample size (n=12/group)
- •No randomization reported
- •Mouse model only — human relevance unknown
Surprising Findings
Glucocorticoid treatment did not increase expression of Atrogin-1 or MuRF1, the two most famous muscle-wasting genes.
For decades, scientists assumed these genes were the main drivers of steroid-induced muscle loss. This study shows they may not even be involved—meaning the entire research direction might need a reset.
Practical Takeaways
If you or a loved one has COPD and is on steroids, ask your doctor about muscle-strengthening programs—this study suggests protecting muscle is critical during flare-ups.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 516 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Animal Cohort Study
Subject
Lower probability
on the GRADE evidence scale
This study tested a new idea in mice — it gave them a special medicine and saw their muscles didn't shrink as much. But it didn't prove the medicine caused the change, because the mice weren't randomly assigned and there were too few of them. It's like noticing your friend's plant looks better after you sang to it — maybe it helped, but you can't be sure.
Major conflicts — industry funding with significant control over the research. Reporting score and overall score cap have been reduced.
Strengths
- Clear experimental groups with defined interventions
- Use of objective measures (micro-CT, muscle weight, gene expression)
- Control groups included for comparison
Weaknesses
- No randomization — groups may differ at baseline
- Blinding status unknown — risk of measurement bias
- Very small sample size (n=12 total)
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
The study tried to be careful by using the same type of mice and measuring things the same way, but it didn't randomly pick which mice got the medicine — that's like choosing your favorite friends to test a new game on. That makes it harder to trust the results, because maybe those mice were just luckier to begin with.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
33 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control group+15/15
- Sample size (n=12)+1.2/20
- Follow-up+10/10
100 / 100
54 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 516 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. This is an animal study with no randomization, no blinding (unknown), and a very small sample size (n=12 total). Without randomization or control for confounders, it cannot establish cause-effect relationships, only observe associations within a specific experimental setup.
Major COI
Major conflicts that significantly reduce study credibility
The study was conducted using a proprietary antibody (CDD866) provided by Versanis Bio, a company with a direct interest in the outcome, and while authors disclosed no conflicts, the funder's provision of the experimental drug without clarification of involvement raises significant bias concerns.
Funders
Conflict Details
Versanis Bio: Provided the experimental compound CDD866 for use in the study
Although all authors declared 'None' for conflicts of interest, the provision of the investigational drug (CDD866) by Versanis Bio — a company with a commercial interest in the success of ActIIB-R blockade — constitutes a major conflict. No details are given about whether the funder influenced study design, analysis, or interpretation. The lack of a funding statement further limits transparency.
Standing
Who’s using this study?
The videos and claims on this site that lean on this study, and the researchers who wrote it.
1 video from Physionic cite this study, drawing 1 claim from it.
- Very strong evidence
Randomized or controlled trials support this claim, alongside consistent supporting evidence.
Evidence